Fobrepodacin

Spero Therapeutics' Phase 3 PIVOT-PO trial for Tebipenem HBr has surpassed 60% enrollment as of December 31, 2024, and is on track for completion in the second half of 2025.

Spero Therapeutics is making significant strides in the development of antibiotics targeting Gram-negative bacteria, with a focus on treatments for complicated urinary tract infections, acute pyelonephritis, and multidrug-resistant infections. Their pipeline includes Tebipenem HBr, an oral carbapenem, and SPR206, an intravenous polymyxin analogue, both undergoing clinical trials.

TenNor Therapeutics' rifasutenizol triple therapy achieved a >90% eradication rate in treating Helicobacter pylori (H. pylori) infection in a Phase III trial.

Spero Therapeutics' Phase 3 PIVOT-PO trial of tebipenem HBr for complicated urinary tract infections remains on track, with enrollment expected to complete in the second half of 2025.

Spero Therapeutics discontinued the development of SPR720 after it failed to meet the primary endpoint in a Phase IIa trial for non-tuberculous mycobacterial pulmonary disease (NTM-PD).